# Cylexin for Reduction of Reperfusion Injury in Infant Heart Surgery

> **NCT00226369** · PHASE2,PHASE3 · COMPLETED · sponsor: **Boston Children's Hospital** · enrollment: 242 (—)

## Conditions studied

- Congenital Heart Defects

## Interventions

- **DRUG:** CY-1503

## Key facts

- **NCT ID:** NCT00226369
- **Lead sponsor:** Boston Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-12
- **Primary completion:** —
- **Final completion:** 2001-06
- **Target enrollment:** 242 (—)
- **Last updated:** 2010-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00226369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00226369, "Cylexin for Reduction of Reperfusion Injury in Infant Heart Surgery". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00226369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*